Table 3 Comparison of NSE levels to predict poor outcome after cardiac arrest and referenced study profiles
Référence | In-hospital CPR (%) | Time of inclusion after CPR, n | Hypothermic therapy, n | Follow-up | Poor outcome definition, and number n | Method used for NSE measurement | NSE sampling time | Cut-off value (ng/mL) | Se | Sp |
|---|---|---|---|---|---|---|---|---|---|---|
Fogel et al. [10] 1997 | Not specified | ICU admission n = 43 | No | 3 months | Remained comatose n = 25 | Radioimmunoassay, Pharmacia LKB | Day 0 Day 1 Day 2 Day 3 | 33 33 33 33 | 25 60 63 65 | 100 100 100 100 |
Martens et al. [21] 1998 | Not specified | > 24 h n = 64 | No | 6 months | Remained comatose n = 35 | Radioimmunoassay, Profilogen | 24 h | 20 | 51 | 89 |
Schoerkhber et al. [11] 1999 | Yes (not specified) | > 6 h n = 56 | No | 6 months | CPC 3-5 n = 28 | Radioimmunoassay, Profilogen | 12 h 24 h 48 h 72 h Peak NSE level 12-72 h | 38 40 25 17 27 | 18 8 48 70 29 | 100 100 100 100 100 |
Rosen et al. [12] 2001 | No | > 24 h n = 66 | No | 1 year | CPC 3-5 n = 42 | Imunoluminometric assay, Byk Sangtec Diagnostica | Day1 Day2 Day3 | 25 25 25 | NM NM NM | 100 100 100 |
Zingler et al. [15]2003 | Yes (not specified) | ICU admission n = 27 | No | 3 months | CPC 4-5 n = 17 | Immunoluminometric assay, Byk Sangtec Diagnostica | Day1 Day2 Day3 Day7 | 48 43 91 39 | 53 91 75 57 | 100 100 100 100 |
Tiainem et al. [14] 2003 | No* | ICU admission n = 70 | Yes n = 36 | 6 months | CPC 3-5 n = 29 | time-resolved immunofluorometric assay (DELFIA, Wallac) | 24 h HT/no HT 36 h HT/no HT 48 h HT/no HT | 31/13 26/13 25/9 | 22/59 30/63 25/76 | 96/100 96/100 96/100 |
Meynaar et al. [13] 2003 | Yes (23%) | ICU admission n = 110 | No | Hospital discharge | Remained comatose n = 81 | time-resolved immunofluorometric assay (DELFIA, Wallac) | Peak NSE level 24-48 h¶ | 25 | 59 | 100 |
Pfeifer et al. [16]2005 | Yes (44%) | > 48 h n = 97 | Not specified | Day 28 | CPC 4-5 n = 70 | Imunoluminometric assays, Byk Sangtec Diagnostica | Day 3 | 65 | 50 | 96 |
Rech at al. [17]2006 | Yes (100%) | >12 h n = 45 | No | 6 months | CPC 4-5 n = 34 | Electrochemiluminescence immunoassay, Roche Mannheim | Between 12-36 h | 60 | 35 | 100 |
Zandbergen et al [2]2006 | Not specified | > 24 h n = 407 | Yes (not specified) | 1 months | CPC 4-5 n = 356 | Immunoluminometric assay, Byk Sangtec Diagnostica | 24 h 48 h 72 h | >33 >33 >33 | 42 52 46 | 100 100 100 |
Auer et al. [18] 2006 | Yes (not specified) | n = 17 | Not specified | Hospital discharge | Death n = 9 | Electrochemiluminescence immunoassay, Roche Mannheim | 48 h | 30 | 79 | 100 |
Grubb et al. [23] 2007 | No | ICU admission n = 143 | Not specified | Hospital discharge | Death | Enzyme immunoassay, Roche Diagnostics | 12 h 24-48 h 72-96 h | NM 71 NM | 14 | 100 |
Reisinger et al. [19]2007 | Yes (44%) | ICU admission n = 177 | Yes n = 20 | 6 months | CPC 4-5 n = 59 | Electrochemiluminescence immunoassay, Roche Mannheim | Peak NSE level Day 0-4 | 80 | 63 | 100 |
Oksanen et al. [20] 2009 | No* | ICU admission n = 90 | Yes n = 90 | 6 months | CPC 3-5 n = 40 | Electrochemiluminescence immunoassay, Roche Mannheim | 24 h 48 h | 41 33 | 20 43 | 100 100 |
Rundgren et al. [9] 2009 | Yes (17%) | ICU admission n = 102 (for NSE cohort) | Yes n = 102 | 6 months | CPC 3-5 n = 46 | Imunoluminometric assay, DiaSorin | 2 h 24 h 48 h 72 h | 31 38 28 27 | 6 11 67 50 | 100 100 100 100 |
Shinozaki et al. [22] 2009 | Yes (27%) | ICU admission n = 80 | Yes n = 45 | 6 months | CPC 3-5 n = 67 | Immunoradiometric assay, Profilogen, DiaSorin | Admission 6 h 24 h | 46 66 40 | 14 19 72 | 100 100 100 |
Steffen et al [42] 2010 | Yes (21%) | ICU admission n = 240 | Yes n = 133 | ICU discharge | CPC 3-5 n = 147 | Electrochemiluminescence immunoassay, Roche Mannheim | 72 h HT/no HT | 79/27 | 50 80 | 100 100 |
Present study | Yes (31%) | > 48 h n = 97 | Yes n = 65 | 3 months | CPC 4-5 n = 72 | Electrochemiluminescence immunoassay, Roche Mannheim | Peak NSE level 24-72 h | 97 | 49 | 100 |